DexCom, Inc. (NASDAQ:DXCM) Holdings Lifted by NewEdge Advisors LLC

NewEdge Advisors LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 122.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,905 shares of the medical device company's stock after acquiring an additional 13,159 shares during the period. NewEdge Advisors LLC's holdings in DexCom were worth $1,859,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after acquiring an additional 56,094 shares during the last quarter. Jennison Associates LLC increased its position in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Norges Bank purchased a new stake in shares of DexCom during the 4th quarter worth about $385,367,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after buying an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in shares of DexCom by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after buying an additional 201,181 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

NASDAQ:DXCM opened at $66.33 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The company has a fifty day moving average price of $74.27 and a 200 day moving average price of $76.66. The stock has a market cap of $26.01 billion, a P/E ratio of 46.38, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Citigroup lifted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $99.00.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. 0.32% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.